Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan

INTRODUCTION: Real-world evidence for the effectiveness and safety of golimumab (GLM) in patients with ulcerative colitis (UC) is limited. The aim of this study was to investigate the 52-week effectiveness and safety of GLM treatment for UC. METHODS: This prospective, multicentre, post-marketing sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Shiro, Asano, Teita, Tanaka, Yoshihito, Sugimoto, Kanami, Yoshigoe, Shinichi, Suzuki, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090977/
https://www.ncbi.nlm.nih.gov/pubmed/37064538
http://dx.doi.org/10.1159/000528185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090977/
https://www.ncbi.nlm.nih.gov/pubmed/37064538
http://dx.doi.org/10.1159/000528185

Ejemplares similares